Physician profile
Rajan Singla
NPI 1215228531
$18,151.54
in general payments reported to CMS, 2019-2025
14 companies · $18K in 2025
The $18K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.20 · 2023: $151 · 2024: $283 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $2,178 · Food and Beverage: $1,843 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,000.00 |
| Travel and Lodging | $2,178.46 |
| Food and Beverage | $1,843.39 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $17,477.06 | 2025 | |
| Galvanize Therapeutics, INC | $202.75 | 2024 | Aliya System |
| Astrazeneca Pharmaceuticals LP | $123.08 | 2024-2025 | Imfinzi, Tezspire |
| Novartis Pharmaceuticals Corporation | $87.62 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $67.16 | 2023-2025 | Opdivo, Krazati |
| Astellas Pharma US INC | $48.65 | 2023-2024 | Xtandi |
| Daiichi Sankyo INC. | $29.64 | 2023 | Injectafer |
| Glaxosmithkline, LLC. | $22.74 | 2023 | Ojjaara |
| Array Biopharma INC | $22.04 | 2025 | Mektovi, Lorbrena, Xalkori |
| Eisai INC. | $21.76 | 2022 | |
| Pfizer INC. | $17.58 | 2023 | |
| Gilead Sciences, INC. | $16.16 | 2025 | Trodelvy |
| Genentech USA, INC. | $15.30 | 2023 | Phesgo, Kadcyla, Perjeta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajan Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.